SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Eichelberg, Christian; Vervenne, Walter L.; Santis, Maria De; Weikersthal, Ludwig Fischer von; Goebell, Peter J.; Lerchenmüller, Christian; Zimmermann, Uwe; Bos, Monique M.E.M.; Freier, W.; Schirrmacher-Memmel, Silke; Staehler, Michael; Pahernik, Sascha; Los, Maartje; Schenck, M.; Flörcken, Anne; Arkel, C. van; Hauswald, Kirsten; Indorf, Martin; Gottstein, Dana; Michel, Maurice Stephan

doi:10.1016/j.eururo.2015.04.017

Cited by 125 publications

(110 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the clinical benefit remains modest. In four phase III studies, AXIS [7], INTORSECT [8], SWITCH-1 [9] and RECORD-1 [6,10], mPFS on second-line therapy ranged from 3.4 to 5.4 months, depending on the prescribed drug. Up to 40% of patients will experience PD after the first two months of treatment [5,11].…”

mentioning

confidence: 99%

Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

Sacré

Barthélémy²,

Korenbaum³

et al. 2015

Acta Oncologica

View full text Add to dashboard Cite

Submit your article to this journal Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (anti-VEGFR-TKI). Efficacy of second-line therapy is usually limited and prognostic and predictive factors at the start of second-line therapy are lacking. To identify the subgroup of patients that will benefit from such treatment remains a challenge. Methods: We performed a multi-institutional, retrospective study of patients who received a second-line therapy after progression on an anti-VEGFR-TKI. Univariate and multivariate analyses were performed in order to identify prognostic factors for progressive disease (PD) as best response, progression-free survival (PFS) and overall survival (OS) on second-line therapy. Results: For the whole cohort of 108 patients, mOS from the start of second-line therapy was 8.9 months while mPFS on second-line therapy was 2.8 months. A total of 49/105 (47%) patients had PD, 50/105 (48%) stable disease (SD) and 6/105 (6%) a partial response (PR). On multivariate analysis, the following markers were associated with improved outcome on second-line therapy: a PFS on first-line therapy 12 months (HR for PFS: 1.961; p ¼ 0.008) (HR for OS: 1.724; p ¼ 0.037) and Fuhrman grade 1-2 tumors (HR for OS: 2.198; p ¼ 0.007). Markers associated with poorer outcome on second-line therapy were: elevated serum lactate dehydrogenase (LDH) levels (HR for PFS: 0.511; p ¼ 0.04) (HR for OS: 0.392; p ¼ 0.017), low albumin (HR for OS: 0.392; p ¼ 0.01) and elevated corrected calcium levels (HR for OS: 0.416; p ¼ 0.01). The impact on OS of the Memorial Sloan Kettering Cancer Centre (MSKCC) and International Renal Cell Carcinoma Database Consortium (IMDC) prognostic scores as calculated at start of second-line therapy was validated in our patient series. Conclusions: Duration of first-line PFS, Fuhrman grade, serum LDH levels, albumin levels, corrected calcium levels and the MSKCC and IMDC scores calculated at start of second-line therapy are prognostic factors for m-ccRCC patients treated with second-line targeted therapy.

show abstract

mentioning

confidence: 99%

Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

Sacré

Barthélémy²,

Korenbaum³

et al. 2015

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…Два исследования изучали последовательное назначе-ние сунитиниба и сорафениба, пазопаниба и сорафе-ниба и не показали достоверных различий в ОВ и ВБП [27,28]. В регистрационном исследовании III фазы ниволумаб продемонстрировал свое преимущество в отношении ОВ пациентов, ранее получавших 1 или несколько линий антиангиогенной таргетной терапии.…”

Section: рис 3 долгосрочная терапия ниволумабом результаты исследоunclassified

Nivolumab as the new standard of metastatic kidney cancer treatment

Матвеев¹

2017

Cancer Urology

View full text Add to dashboard Cite

Key words: kidney cancer, nivolumab, immunotherapyВведение В структуре онкологической заболеваемости зло-качественные новообразования почки составляют 3,6 %, занимая 9-е место. В России заболеваемость раком почки составляет 10,2 на 100 тыс. населения. По величине прироста заболеваемости данная нозо-логия занимает 3-е место. Ежегодно от рака почки умирают около 8 тыс. россиян [1].Несмотря на совершенствование методов диагнос-тики и миграции стадии заболевания в сторону повы-шения частоты выявления локализованных форм опу-холи, около трети пациентов имеют синхронные отдаленные метастазы на момент установления диаг-ноза и у 20-25 % развиваются метахронные метастазы в разные сроки после хирургического лечения [2,3].Наиболее распространенным (85 %) вариантом рака почки является светлоклеточный, характеризую-щийся мутацией гена VHL. Существующие достижения в терапии и рекомендации по лечению диссеминиро-ванного рака почки относятся именно к светлоклеточ-ному типу.Рак почки считается иммуногенной опухолью, что связано с редкими случаями спонтанных регрессий метастазов после удаления первичной опухоли и скром-ными успехами цитокиновой иммунотерапии -лече-ния с использованием интерферона альфа и интерлей-кина 2. Низкая эффективность цитокиновой терапии и ее высокая токсичность послужили основанием для отказа от ее применения с появлением таргетных антиангиогенных препаратов, нацеленных на фактор роста эндотелия сосудов (vascular endothelial growth factor, VEGF) и сигнальный путь мишени рапамицина млекопитающих (mTOR). Использование ингибито-ров тирозинкиназ и mTOR продемонстрировало

show abstract

“…There are no randomized trials showing the benefit of metastasectomy in RCC with oligometastatic disease; however, among patients with metachronous metastases after nephrectomy, about one-third are eligible for metastasectomy and several large cohorts report 50% five-year survival following complete resection of metastases. [82][83][84] Based on available observational data, patients most likely to benefit from metastasectomy are those diagnosed with metastases after at least a two-year disease-free interval, those with isolated metastases, and those with surgically favourable metastatic locations (e.g., lung, thyroid, and adrenal). 85 A period of observation is reasonable to confirm that the metastatic disease is not rapidly progressing.…”

Section: Role Of Local Therapy In Oligometastasesmentioning

confidence: 99%

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

North

Basappa

Bjarnason

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Abstract: ClinicalTrials.gov identifier NCT00732914, www.clinicaltrials.gov.

Cited by 125 publications

References 43 publications

Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

Nivolumab as the new standard of metastatic kidney cancer treatment

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

Contact Info

Product

Resources

About